Abcam, ab130280, Recombinant Human GLP-1R protein

Size: 100µg
Recombinant Human GLP-1R protein is a Human Fragment protein, in the 24 to 145 aa range, expressed in Escherichia coli, with >90%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, WB.
Key facts
Purity:>90% Densitometry,
Endotoxin level:< 1 EU/µg,
Expression system:Escherichia coli,
Tags:His tag N-Terminus,
Applications:SDS-PAGE, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:No,
Accession:P43220,
Animal free:No,
Carrier free:No,
Species:Human,
Reconstitution:Reconstitute at 0.5 mg/mL in 0.1 M acetate buffer, pH 4.0,
Storage buffer:Constituents: 0.41% Sodium acetate

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GLP-1R also known as glucagon-like peptide-1 receptor plays an important role in glucose metabolism. This receptor is a member of the class B family of G protein-coupled receptors (GPCRs) and has a molecular mass of approximately 53 kDa. GLP-1R is expressed in pancreatic beta cells the central nervous system and other peripheral tissues. It binds to GLP-1 a peptide hormone initiating a cascade of intracellular signaling that is essential for its physiological functions.
Biological function summary
GLP-1R serves as an important player in the regulation of insulin secretion. It is not part of a complex but acts as a standalone receptor. When GLP-1 binds to GLP-1R it triggers the activation of adenylyl cyclase increasing cyclic AMP levels and facilitating insulin secretion. This process is glucose-dependent meaning that it enhances insulin release only when blood glucose levels are elevated therefore preventing hypoglycemia.
Pathways
GLP-1R is an integral component of the incretin signaling pathway and the insulin signaling pathway. Through these pathways it influences key metabolic processes. Incretin hormones like GLP-1 improve glucose-dependent insulin secretion involving proteins such as GLP-1R and other incretin-related receptors. Additionally GLP-1R interacts with insulin receptor pathways to modulate glucose uptake in tissues.
GLP-1R has significant implications in type 2 diabetes and obesity. Its role in enhancing insulin secretion makes it a target for therapeutic interventions using GLP-1 analogs like liraglutide. Liraglutide structure mimics natural GLP-1 effectively agonizing GLP-1R to achieve desired metabolic outcomes. Additionally liraglutide GLP-1 analog therapies show promise in obesity management by influencing appetite regulation through GLP-1R pathways in the central nervous system.